Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential neoadjuvant ifosfamide and doxorubicin in localized high-grade soft tissue sarcoma
2020-002777-95Phase 2Active
- Sponsor
- Oslo University Hospital
- Start
- Jun 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ifosfamide and doxorubicin in soft tissue sarcoma (STS), sponsored by Oslo University Hospital. Primary endpoint: Overall response rate (radiologic). Started Jun 2020; status: active.
02
Drugs
ifosfamidedoxorubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2020-002777-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002777-95.